http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115141265-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_140efb7e2a330be53d94bda6ad75cbe5 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4711 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-107 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 |
| filingDate | 2022-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34b7d15d5d84c3f4fdc475ce504f2793 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f2fba55fbe4bd45a1a58619ad03e9ff http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be424c6728c49df52a2b1f8e3b66d8a7 |
| publicationDate | 2022-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-115141265-A |
| titleOfInvention | Quaternary allosteric pyruvate isoenzyme M2-type activating peptide and its application in reversing the Warburg effect and tumor chemotherapy |
| abstract | The invention provides a tetrameric allosteric pyruvate isoenzyme M2 activating peptide and its use for changing the Warburg effect and the definition of tumor chemotherapy in the biomedical field. Allosterically activating peptides of pyruvate isoenzyme M2 tetramers contain a serine pattern coated with N-acetylglycosides, a self-assembly mechanism capable of forming hydrophobic nanocomplexes with fluorescent signaling mechanisms and coacervation Function. The polypeptide can react with the OGA enzyme synthesized in the renal cancer region to absorb N-acetylglucosamine, thereby expressing the serine activator of the tetramer of pyruvate isoenzyme M2, and promoting the conversion of pyruvate isoenzyme M2 from bilateral to quadruple, Start the self-assembly movement. During the self-aggregation process of nanocomposites, nanocomposites can be formed in the absence of water, increasing the retention time of serine phase and the intensity of fluorescent AIE signal, thus completing the work of changing the Warburg phenomenon and improving chemical sensitivity . The present invention is a novel method for treating renal cell carcinoma. |
| priorityDate | 2022-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 138.